Pneumococcal infections are an important cause of morbidity/mortality in children with sickle cell disease (SCD). Pneumococcal conjugate vaccines linked to protein carriers are immunogenic in healthy infants < 2 yrs of age, but have not been evaluated in children with SCD. Infants with SCD were immunized with a 7-valent pneumococcal polysaccharide-protein conjugate vaccine (CRM; cross-reacting diphtheria mutant) at 2, 4, and 6 mos. Type specific antibodies were measured by ELISA after pre-absorption with C-polysaccharide. No side effects have been observed. This vaccine appears to be safe and immunogenic, and should provide protection against pneumococcal infections in infants with SCD. (Funded in part by Lederle-Praxis Biologicals.) Table
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
O'Brien, K., Winkelstein, J., Santosham, M. et al. IMMUNOGENICITY OF A PNEUMOCOCCAL PROTEIN CONJUGATE VACCINE IN INFANTS WITH SICKLE CELL DISEASE. ▴ 946. Pediatr Res 39 (Suppl 4), 160 (1996). https://doi.org/10.1203/00006450-199604001-00968
Issue Date:
DOI: https://doi.org/10.1203/00006450-199604001-00968